Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11717665 | 0.82 | IDO1 (0.38) | TAAR1IDO1TSHRRIPK1ALDH1A1 | |
| SCHEMBL11066668 | 0.77 | TAAR1 (0.54) | TAAR1IDO1TSHRCYP2A13PYCR1 | |
| SCHEMBL7847384 | 0.76 | TRPA1 (0.35) | IDO1TSHRALDH1A1 | |
| SCHEMBL1691374 | 0.76 | RIPK1 (0.47) | TAAR1IDO1TSHRNR3C1CYP2A13 | |
| SCHEMBL5697510 | 0.73 | TAAR1 (0.43) | TAAR1IDO1TSHRCYP2A13PYCR1 | |
| SCHEMBL15638695 | 0.73 | TAAR1 (0.50) | TAAR1IDO1TSHRNR3C1CYP2A13 | |
| SCHEMBL18623577 | 0.73 | TAAR1 (0.44) | TAAR1IDO1TSHRNR3C1CYP2A13 | |
| SCHEMBL2401345 | 0.73 | RIPK1 (0.45) | TAAR1IDO1TSHRNR3C1CYP2A13 | |
| SCHEMBL30388724 | 0.73 | RIPK1 (0.45) | TAAR1IDO1TSHRNR3C1CYP2A13 | |
| SCHEMBL28754249 | 0.73 | TAAR1 (0.44) | TAAR1IDO1TSHRNR3C1CYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4540238-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20250115582-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024059524-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023244818-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-112500517-A | Oil-soluble super-heavy oil viscosity reducer and preparation method and application thereof | 山东德仕化工有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-101516884-A | Octahydropyrrolo [3, 4-C] pyrrole derivatives an their use as antiviral agents | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008135826-A2 | 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LIMITED (GB) | 2008-11-13 | — | — | WO | disclosed |
| CN-101084198-A | Substituted amino-pyrimidones and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-101084199-A | Substituted amino-compounds and uses thereof | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-101039947-A | Inhibitors of hcv replication | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | CN | disclosed |
| CN-1894235-A | N-(4-carbamimidoyl-benzyl) -2-alkoxy-2-heterocyclyl acetamides as inhibitors of the formation of coagulation factors xa, ixa and thrombin induced by factor viia | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | TAAR1 4854/4885IDO1 4640/4885TSHR 4273/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TAAR1 4854/4885IDO1 4640/4885TSHR 4273/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | TAAR1 1946/4885IDO1 1538/4885TSHR 3678/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | TAAR1 3408/4885IDO1 392/4885TSHR 2143/4885 |
| US-20250115582-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | TAAR1 2209/4885IDO1 3139/4885TSHR 4501/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TAAR1 4854/4885IDO1 4640/4885TSHR 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.